The 20 Best Multiple Myeloma Doctors Near Me in Cumberland, MD

As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 43 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant. Dr. Narang is board certified in American Board Of Internal Medicine.

Carol Ann Huff, M.D., is an Associate Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine and Medical Director for the Johns Hopkins Kimmel Cancer Center. After completing a Bachelor of Science in Zoology at Duke University in Durham, NC, Dr. Huff received her medical degree from Baylor College of Medicine in Houston. She completed her internship and residency in Internal Medicine at Johns Hopkins and was an Assistant Chief of Service in the Department of Medicine before completing her fellowship training in the Department of Oncology at Johns Hopkins University. Dr. Huff is a nationally-recognized expert in the treatment of multiple myeloma and amyloidosis and in the development of new biologically-based treatment strategies. She has sought to better understand the mechanisms for recurrence and the inability to cure these diseases. Through this research, the identification of a myeloma cancer stem cell has emerged, and efforts to target these cells through combination therapy in clinical trials are ongoing. In collaboration with Dr. William Matsui, Dr. Huff has identified a flow cytometric-based blood analysis for multiple myeloma patients that can be used to quantify the number of myeloma cancer stem cells and track how these cells respond to treatment. Their efforts have revealed that changes in the number of myeloma cancer stem cells can predict recurrence in myeloma patients before clinical evidence of recurrence is detectable. Using this blood analysis, as well as growth of these cells from bone marrow samples taken from patients with myeloma, they have begun studying therapeutic strategies to target these cells based on cell surface markers and enzymatic pathways that are important to the survival of myeloma stem cells. Dr. Huff is the recipient of multiple awards for clinical and teaching excellence including the Kimmel Cancer Center's Director’s Teaching Award in Oncology in both 2006 and 2012. During her medical school training, Dr. Huff was the recipient of a Howard Hughes Medical Institute-National Institutes of Health (NIH) fellowship. She has received grant support from the NIH, Multiple Myeloma Research Foundation, and Leukemia and Lymphoma Society. and LLS, and is the principal investigator of numerous investigator-initiated and industry- sponsored clinical trials. She is the author of numerous publications and book chapters not only on multiple myeloma and related disorders, but also on bone marrow transplantation and a range of topics related to internal medicine and oncology. Her current research efforts involve active collaboration with the preclinical laboratories in the development and testing phases of new therapeutic approaches, as well as a lead effort in the national African American Myeloma Consortium seeking to better understand genetic determinants of the disease. Dr. Huff is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, and Plasmacytoma. Dr. Huff is board certified in American Board Of Internal Medicine.

Ashraf Badros is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Badros is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Plasmacytoma, and Bone Marrow Transplant.

Djordje Atanackovic is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Atanackovic is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Mehmet Kocoglu is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Kocoglu is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Aaron Rapoport is a Hematologist practicing medicine in Baltimore, Maryland. Dr. Rapoport is rated as an Elite provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Philip Imus is an oncologist in the Baltimore area, caring for patients with hematologic malignancies. Dr. Imus received his undergraduate degree (cum laude) in English from Rice University. He earned his M.D. from Columbia University College of Physicians and Surgeons. He completed his residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center and performed a fellowship in oncology at Johns Hopkins. Dr. Imus is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Christian Gocke is a Hematologist practicing medicine in Baltimore, Maryland. He has been practicing medicine for over 17 years. Dr. Gocke is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Gocke is board certified in American Board Of Internal Medicine.

Dr. Syed Abbas Ali is a medical oncology specialist in Baltimore, caring for patients with cancer. Dr. Ali earned his M.B.B.S. at The Aga Khan University. He completed his residency at the University of Arkansas for Medical Sciences and performed a fellowship in medical oncology at the National Institutes of Health. Dr. Ali is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Gastrostomy.

Dr. Ralph V. Boccia is a hematologist affiliated with Sibley Memorial Hospital, Suburban Hospital, Shady Grove Adventist Hospital, Holy Cross Hospital and MedStar Georgetown University Hospital, where he is a clinical associate professor of medicine for the University, as well as the medical director of the International Oncology Network (ION) Clinical Research Program and the chairman of ION’s Medical Advisory Panel. He practices out of the Center for Cancer and Blood Disorders, of which he is the founder and medical director, located in Bethesda, Maryland and Germantown, Maryland. Dr. Boccia earned his medical degree from the Autonomous University of Guadalajara School of Medicine. He completed a residency in internal medicine at Kern Medical Center, followed by a fellowship in hematology, oncology and bone marrow transplant at the combined UCLA-Veterans Administration Program and The National Cancer Institute at the National Institutes of Health. Dr. Boccia is a member of the American College of Physicians, the American Society of Clinical Oncology, the American Society of Hematology and the American Society for Blood and Marrow Transplantation. Dr. Boccia has been listed as a Top Doctor by Washingtonian Magazine and Consumers’ Checkbook Magazine since 1992. He has also been recognized as a Super Doctor by The Washington Post Magazine and a Regional Top Doctor for Washington, D.C., Baltimore and Washington-Baltimore by Castle Connolly. Dr. Boccia has contributed to various articles with his research, published in journals such as Annals of Internal Medicine, Journal of Clinical Oncology and The Lancet. Recent News Articles and Media Coverage Bladder cancer trends in Montgomery and Prince George's counties: Welcome news - and 3 facts you need to know. NJ.com (08/16/2016) RCCA Expands to Maryland to Become One of the Nation's First Multi-State Oncology/Hematology Physician-Owned and -Operated Networks. OncLive (10/06/2015). Dr. Boccia is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Anemia, Multiple Myeloma, Thrombocytopenia, Adult Immune Thrombocytopenia, and Splenectomy. Dr. Boccia is board certified in American Board Of Internal Medicine.

"George A. Sotos, M.D., is the chief of hematology and oncology at Suburban Hospital, as well as a member of Suburban's Cancer Committee and the coordinator of Multidisciplinary Cancer Conferences. Dr. Sotos is a partner of Maryland Oncology & Hematology in Rockville, Maryland. Dr. Sotos has expertise in medical oncology and hematology, as well as chemotherapy. Dr. Sotos earned his Master of Science in Physiology from Georgetown University, followed by his medical degree from the Medical College of Virginia. He completed a residency in internal medicine with University of Texas Southwestern Medical Center, followed by a fellowship in medical oncology with the National Cancer Institute of the National Institutes of Health. Dr. Sotos is a fellow of the American College of Physicians, as well as a member of the Montgomery County Medical Society, the Medical and Chirurgical Faculty of the State of Maryland, and the American Society of Clinical Oncology. He is also a member of the oncology specialty panel for Johns Hopkins Medicine's Formulary Management Committee and previously served as a member of Suburban Hospital's Medical Staff Executive Committee, Provider Quality Committee and Physician Advisory Board. Dr. Sotos has been named a Top Doctor by Washington Consumers' Checkbook and a Super Doctor by the Washington Post magazine. Castle Connolly has also named him a Top Doctor in the Washington, D.C., Baltimore and Washington-Baltimore areas. Dr. Sotos has contributed to numerous publications on medical oncology and hematology topics. Selected Publications Rotello, L, Albrant, D, Nossuli, K, Sotos, G, Samet, C, Rainey, T. ""Impact of a Hospital-Wide Pharmacy Implemented Weight-Based Dosing Protocol for Erythropoietin."" Chest, 124:4 (Suppl):182S (Abstract), 2003. Sotos, George A. ""Ars Brevis."" Journal of Clinical Oncology, 2013; 31:14; 1792-1794; http://jco.ascopubs.org/content/31/14/1792.full.pdf+html". Dr. Sotos is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 64 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Multiple Myeloma, and Endometrial Cancer. Dr. Sotos is board certified in American Board Of Internal Medicine.

John Wallmark is a Hematologist Oncology provider practicing medicine in Rockville, Maryland. Dr. Wallmark is rated as a Distinguished provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 47 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Multiple Myeloma, and Colorectal Cancer. Dr. Wallmark is board certified in American Board Of Internal Medicine.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Fuchs is board certified in American Board Of Internal Medicine.

Dr. DeZern is a Professor of Oncology and Medicine at The Johns Hopkins University School of Medicine. She is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. DeZern has expertise in aplastic anemia, myelodysplastic syndromes, paroxysmal nocturnal hemoglobinuria, acute myeloid leukemia, and bone marrow transplantation. Dr. DeZern received her medical degree at The Johns Hopkins University School of Medicine. She completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology and hematology, as well as obtained a Masters in Clinical Investigations at the Bloomberg School of Public health. Dr. DeZern is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. Dr. DeZern’s principle research activities consist of designing and conducting clinical trials that test investigational new therapies and approaches in the treatment of bone marrow failure (aplastic anemia and myelodysplastic syndromes). She has specific expertise in the use of alternative donor bone marrow transplantation in patients with severe aplastic anemia and trials of novel therapeutics for patients with myelodysplastic syndromes. Additionally, she has taken a rigorous approach to the study of diagnostics and supportive case (such as transfusion practices) in these patient populations. She is or has been the Principal Investigator for a number of multicenter trials in collaboration with the MDS Clinical Research Consortium, the Eastern Co-operative Oncology Group (ECOG)-ACRIN and now the Bone Marrow Trials Clinical Trials Network (BMTCTN). She is the Study Chair for the multi-site BMTCTN study (CHAMP) investigating the role of haploidentical donor transplantation using post-transplantation cyclophosphamide in patients with relapsed several aplastic anemia. Dr. DeZern is the local PI as well as the Deputy Chair for The National MDS Study, a collaborative natural history study of the NHLBI and the NCI. As a clinical investigator with a focus on translation of novel treatments to the clinic, Dr. DeZern’s goal is to improve outcomes for patients with bone marrow failure at the bedside and in her research environment. Dr. Dezern is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dezern is board certified in American Board Of Internal Medicine.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Transplant. Dr. Swinnen is board certified in American Board Of Internal Medicine.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Non-Hodgkin Lymphoma, and Myelodysplastic Syndrome (MDS). Dr. Jones is board certified in American Board Of Internal Medicine.

Mark J. Levis, M.D., Ph.D., professor of oncology, medicine and pharmacology in the Division of Hematologic Malignancies at the Johns Hopkins University School of Medicine, co-directs the Hematologic Malignancies and Bone Marrow Transplantation Program and directs the Adult Leukemia Service at the Johns Hopkins Sidney Kimmel Cancer Center. In addition to his role within the Kimmel Cancer Center, he serves on the faculty for the Johns Hopkins Graduate Training Program in Cellular and Molecular Medicine, a Ph.D. program that prepares scientists to conduct laboratory research at the cellular and molecular level that is designed to have a direct impact on the understanding of human diseases. Dr. Levis has expertise in acute and chronic myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes. Dr. Levis received his medical degree at the University of California, San Francisco School of Medicine, where he also earned his Ph.D. in Biochemistry. He completed a residency in internal medicine at Johns Hopkins, followed by fellowships in medical oncology. Dr. Levis is a member of the American Society of Hematology, the American Society of Clinical Oncology and the European Hematology Association. He is an ad hoc member of the Oncology Drug Advisory Committee, as well as an ad hoc manuscript referee for peer-reviewed journals such as New England Journal of Medicine; Leukemia; Clinical Cancer Research; and The American Journal of Hematology. Dr. Levis has earned numerous awards, such as the Daniel Nathans Research Award from Johns Hopkins University, the Osler Housestaff Teaching Award, the Director's Teaching Award in Clinical Science, and the Advanced Clinical Research Award from the American Society of Clinical Oncology. Dr. Levis’ laboratory research focuses on the development of molecularly-targeted therapies for leukemia. He is actively involved in the pre-clinical and clinical development of small molecule inhibitors of protein kinases, including FLT3. The research involves studying the biochemical effects of these inhibitors on samples taken from leukemia patients, with the broad goal of identifying and validating novel molecular therapeutic targets in these hematopoietic malignancies. While Dr. Levis plays a key role in the pre-clinical development of these therapies, he is particularly interested in translating this research to the bedside of his patients by using correlative studies to incorporate these novel therapies into existing treatments. In addition to his work in both the clinic and the laboratory, Dr. Levis has also conducted talks, mentorship and teaching lectures, and published extensively in the top journals in his field, including Leukemia; Blood; and the New England Journal of Medicine. Dr. Levis is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

"Shannon C. O'Connor, M.D., is a medical oncologist with Suburban Hospital. She practices out of Maryland Oncology Hematology. Dr. O'Connor has expertise in hematology and medical oncology with a special focus in women's health, including breast cancer and gynecologic cancers. Dr. O'Connor earned her Master's Degree in Physiology at Georgetown University, followed by her medical degree from St. George's University School of Medicine. She completed a residency at Washington Hospital Center, as well as a fellowship in hematology and oncology. Dr. O'Connor is a member of the American Society of Clinical Oncology, the American Society of Hematology, the Montgomery County Medical Society and the American Medical Association. Selected Publications Catlett JP1, Williams SA, O'Connor SC, Krishnan J, Malkovska V. ""Primary lymphoma of bone: an institutional experience."" Leuk Lymphoma. 2008 Nov;49(11):2125-32. doi: 10.1080/10428190802404030.". Dr. O'connor is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. She is also highly rated in 46 other conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, and Breast Cancer. Dr. O'connor is board certified in American Board Of Internal Medicine.

Andrew Mener, M.D. has experience treating a wide range of adult hematologic and oncologic disorders, with a particular interest in treating breast, lung, gastrointestinal and hematologic malignancies. He takes great pride in delivering personalized, compassionate care and strives to effectively explain complex treatment options to his patients. He strongly believes in the importance of treating each and every patient as an individual. Learn more at marylandoncology.com. Dr. Mener is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 48 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Severe Congenital Neutropenia. Dr. Mener is board certified in American Board Of Internal Medicine.

Edward Lee, M.D. was named one of Baltimore’s “Top Doc’s” by Baltimore Magazine in 2000 and 2002. After receiving additional training in Hematology and Medical Oncology at the University of Maryland in 1984, he remained on faculty until 1997. During his academic career, Dr. Lee was chairman of the training program for five years, started the Bone Marrow Transplant Program at the University of Maryland in 1993, and wrote 50 original articles on leukemia, lymphoma and related diseases. In 1997, Dr. Lee entered private practice as Chief of Hematology and Medical Oncology at Sinai Hospital. Practicing in Columbia since 2001, Dr. Lee treats patients with all forms of cancer, maintaining a particular interest in breast cancer, leukemia, and lymphomas. Learn more at marylandoncology.com. Dr. Lee is rated as an Advanced provider by MediFind in the treatment of Multiple Myeloma. He is also highly rated in 42 other conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Paget Disease of the Breast, Breast Cancer, and Primary Lymphoma of the Brain. Dr. Lee is board certified in American Board Of Internal Medicine.